"The voice for cancer physicians and their patients in Massachusetts."

FDA grants accelerated approval to mobocertinib for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations

16 Sep 2021 8:00 AM | Katy Monaco (Administrator)

The US Food and Drug Administration (FDA) has approved EXKIVITY™ (mobocertinib), the first oral therapy to target epidermal growth factor receptor (EGFR) exon 20 insertion mutations in metastatic non-small cell lung cancer (NSCLC). More information.  September 15, 2021. Press Release.

© Copyright.  All rights reserved. 

Massachusetts Society of Clinical Oncologists

P.O. Box 549154, Waltham, MA, 02454
Tel: 781.434.7329 | Fax: 781.464.4896 | email: msco@mms.org

Powered by Wild Apricot Membership Software